THE SCIENCE OF VYEPTI (eptinezumab-jjmr)

CGRP and receptors visual

Inside the brain, there is a protein called CGRP, which stands for calcitonin gene-related peptide.

CGRP attaching toCGRP receptors

CGRP attaches to CGRP receptors and activates them, a process which is thought to play a large role in causing migraine.

VYEPTI blocking CGRP from attaching to receptors

VYEPTI binds to CGRP, preventing it from activating CGRP receptors.

The relationship between your body’s response to the medication and the way VYEPTI prevents migraine is unknown.

Inside the brain, there is a protein called CGRP, which stands for calcitonin gene-related peptide.

CGRP attaches to CGRP receptors and activates them, a process which is thought to play a large role in causing migraine.

VYEPTI binds to CGRP, preventing it from activating CGRP receptors.

The relationship between your body’s response to the medication and the way VYEPTI prevents migraine is unknown.

References:
  1. VYEPTI [package insert]. Deerfield, IL: Lundbeck Seattle BioPharmaceuticals, Inc.
  2. Ho TW, Edvinsson L, Goadsby PJ, et al. CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol.2010;6:573-582.
  3. Dodick DW, Lipton RB, Silberstein S, Goadsby PJ, et al. Eptinezumab for prevention of chronic migraine: a randomized phase 2b clinical trial. Cephalalgia. 2019;39(9):1075-1085.
IMPORTANT SAFETY INFORMATION
AND APPROVED USE

Do not receive VYEPTI if you have a known allergy to eptinezumab-jjmr or its ingredients.

APPROVED USE

VYEPTI is a prescription medicine used for the preventive treatment of migraine in adults.

VYEPTI may cause allergic reactions. Call your healthcare provider or get emergency medical help right away if you have any symptoms of an allergic reaction: rash, swelling of your face, lips, tongue, or throat, if you have trouble breathing, hives or redness in your face.

Before starting VYEPTI, tell your healthcare provider about all your medical conditions, including if you are pregnant or plan to become pregnant, or you are breastfeeding or plan to breastfeed.

Tell your healthcare provider about all the medicines you take, including any prescription and over-the-counter medicines, vitamins, or herbal supplements.

The most common side effects of VYEPTI include stuffy nose and scratchy throat, and allergic reactions.

These are not all the possible side effects of VYEPTI. Tell your healthcare provider if you have any side effect that bothers you or that does not go away.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

For more information, please see the Prescribing Information and Patient Information.

APPROVED USE

VYEPTI is a prescription medicine used for the preventive treatment of migraine in adults.

IMPORTANT SAFETY INFORMATION
AND APPROVED USE

Do not receive VYEPTI if you have a known allergy to eptinezumab-jjmr or its ingredients.

VYEPTI may cause allergic reactions. Call your healthcare provider or get emergency medical help right away if you have any symptoms of an allergic reaction: rash, swelling of your face, lips, tongue, or throat, if you have trouble breathing, hives or redness in your face.

Before starting VYEPTI, tell your healthcare provider about all your medical conditions, including if you are pregnant or plan to become pregnant, or you are breastfeeding or plan to breastfeed.

Tell your healthcare provider about all the medicines you take, including any prescription and over-the-counter medicines, vitamins, or herbal supplements.

The most common side effects of VYEPTI include stuffy nose and scratchy throat, and allergic reactions.

These are not all the possible side effects of VYEPTI. Tell your healthcare provider if you have any side effect that bothers you or that does not go away.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

For more information, please see the Prescribing Information and Patient Information.